Wall Street brokerages predict that Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) will report sales of $6.47 million for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Pieris Pharmaceuticals’ earnings. The highest sales estimate is $8.90 million and the lowest is $2.50 million. Pieris Pharmaceuticals posted sales of $13.26 million during the same quarter last year, which would indicate a negative year over year growth rate of 51.2%. The company is scheduled to report its next earnings results on Monday, May 10th.
According to Zacks, analysts expect that Pieris Pharmaceuticals will report full-year sales of $28.00 million for the current fiscal year, with estimates ranging from $24.41 million to $30.00 million. For the next financial year, analysts anticipate that the firm will post sales of $22.26 million, with estimates ranging from $11.88 million to $29.90 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Pieris Pharmaceuticals.
Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings results on Monday, March 29th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.02). Pieris Pharmaceuticals had a negative net margin of 59.11% and a negative return on equity of 55.20%.
Institutional investors and hedge funds have recently made changes to their positions in the stock. ProShare Advisors LLC purchased a new position in shares of Pieris Pharmaceuticals during the fourth quarter valued at approximately $29,000. Principal Financial Group Inc. acquired a new position in Pieris Pharmaceuticals during the fourth quarter worth approximately $33,000. Navis Wealth Advisors LLC acquired a new position in Pieris Pharmaceuticals during the fourth quarter worth approximately $40,000. Squarepoint Ops LLC acquired a new position in Pieris Pharmaceuticals during the third quarter worth approximately $36,000. Finally, Jane Street Group LLC acquired a new position in Pieris Pharmaceuticals during the third quarter worth approximately $37,000. 57.46% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ PIRS opened at $2.64 on Thursday. Pieris Pharmaceuticals has a 12-month low of $1.95 and a 12-month high of $3.64. The company has a market capitalization of $147.76 million, a PE ratio of -4.98 and a beta of 1.40. The firm’s 50-day moving average is $2.67 and its two-hundred day moving average is $2.63.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
See Also: What does the Dogs of the Dow mean?
Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
